All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Analysis of the Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Intermediate and Advanced Hepatocellular Carcinoma

Author(s): Zheng Cao, Xuefeng Li, Jiahui Gui, Xuemei Li, Fayun Sun, Tiezheng Jia, Huaxiang Zhang and Yanhuan Zhang*
Department of Pharmacy, 1Administrative Department, Guoyang County People’s Hospital, Bozhou, Anhui Province 233600, China

Correspondence Address:
Yanhuan Zhang, Department of Pharmacy, 1Administrative Department, Guoyang County People’s Hospital, Bozhou, Anhui Province 233600, China, E-mail: 175822174@163.com


To analyze the clinical efficacy and assess the safety of karelizumab combined with apatinib in the treatment of intermediate and advanced hepatocellular carcinoma. Forty-four patients diagnosed with intermediate and advanced hepatic malignant tumors in our hospital were retrospectively collected from January 2019 to June 2020, and the patients were divided into karelizumab combined with abatinib group A (22 patients) and abatacept group B (22 patients) according to the different treatment methods. Baseline data, clinical outcomes after 1 mo, 3 mo and 6 mo of follow-up were compared between the two groups. The follow-up period was up to December 31, 2022 and patients were counted for progression-free overall survival, and progression-free survival. Treatment-related adverse events were assessed using the common terminology criteria for adverse events. Risk factors affecting progression-free survival were analyzed using univariate and multivariate analysis with Cox risk regression model. Treatment-related adverse events were assessed using the common terminology criteria for adverse events. The best outcome of each patient was recorded; complete response, partial response, stable disease and progressive disease at the best outcome were 9 (20.45), 20 (45.45 %), 7 (15.91 %) and 8 (18.18 %), respectively. The objective remission rate of karelizumab combined with apatinib in the treatment of intermediate and advanced hepatocellular carcinoma is high and the safety is good, which lays the foundation for the subsequent clinical trials to be carried out.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 69022

Indian Journal of Pharmaceutical Sciences received 69022 citations as per google scholar report